ホームページへ

ページ4 - 最高の胃癌医師 - トップ129名の医師

コンテンツはBookimed編集ポリシーを満たし、以下により医学的にレビューされています

Fahad Mawlood

Sebastian Keil

  • 4.7 優秀 61 レビュー
  • 22年の経験
  • ドイツ, ゾーリンゲン, Medical Center in Solingen
  • Professor Dr. Sebastian Keil is a recognized expert in the field of interventional radiology and is considered one of the leading specialists in Germany and in Europe. He is a professional in his field, thanks to whom many patients receive timely diagnosis and effective treatment. Professor Keil and his team of specialists have extensive knowledge of anatomy, physiology and pathology, as well as an understanding of the various methods of performing and interpreting radiological examinations.
  • 続きを読む
胃切除術
$26,547.53 - $26,547.53
胃切除術
$21,930.57 - $21,930.57
情報

Phd Viola Fox

  • 4.7 優秀 61 レビュー
  • 14年の経験
  • ドイツ, ゾーリンゲン, Medical Center in Solingen
  • フォックス・ヴィオラ博士は、BKZゾーリンゲン血液腫瘍科・緩和医療科の主任医師です。同クリニックは、認定された集学的腫瘍センターです。フォックス博士は、ドイツおよびヨーロッパにおける腫瘍性疾患の薬物療法の第一人者であり、15年以上の臨床経験を有しています。

    同博士は、ドイツ腫瘍学・血液腫瘍学会(GDHO)、ドイツ医師会、およびアメリカがん研究学会に所属しています。また、分子生物学の研究にも従事しており、その研究成果はがん治療および分子診断の発展に貢献しています。

    主な専門領域は、化学療法、免疫療法、分子標的療法、および放射線療法です。フォックス博士は、革新的な治療法と患者への細やかな配慮で知られています。その取り組みにより、高い治癒率を達成し、同僚からの高い評価を得ています。

  • 続きを読む
胃切除術
$26,547.53 - $26,547.53
胃切除術
$21,930.57 - $21,930.57
情報

Axel Stang

  • 4.6 優秀 130 レビュー
  • 30年の経験
  • 認定:
  • ドイツ, ハンブルク, Asklepios Hospital Barmbek
  • Dr. Axel Stang is a professor, Head Physician of Asklepios Barmbek Clinic, with a specialization in internal medicine, oncology, and hematology. He conducts antibody and molecular therapies to reduce tumor size, and is a member of multiple organizations and societies. Dr. Stang has published articles on the effectiveness of radiofrequency ablation in treating of metastatic colon cancer, and was a member of a research group that studied the effects of liver embolization. Patients can submit a request on the Bookimed website to get a consultation with the professor.

  • 続きを読む
ガンマナイフ
$10,388.16 - $12,696.64
胃癌化学療法
$3,116.45 - $4,039.84
情報

Yusuf Acikgoz

  • 4.9 優秀 7 レビュー
  • 10年の経験
  • トルコ, アンカラ, Lokman Hekim University Ankara Hospital
  • Associate Professor Dr. Yusuf AÇIKGÖZ
    Specialization: Medical Oncology

    Education:

    • 2004-2011: İnönü University Faculty of Medicine
    • 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
    • 2017-2022: Health Sciences University, Medical Oncology

    Professional Experience:

    • 2016-2017: Bingöl City Hospital, Internal Medicine
    • 2021-2022: Health Sciences University, Medical Oncology
    • 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
    • 2023-2024: Ohio State University, Medical Oncology
    • 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

    Clinical Trials, Courses, Certifications:

    Clinical Trials:

    • 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
    • 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

    Courses:

    • 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
    • 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
    • 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
    • 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
    • 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

    Certifications:

    • Ongoing: ECFMG Certification
    • 2024: CITI Responsible Conduct of Research (The Ohio State University)
    • 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
    • 2024: CITI Human Subjects Protection (The Ohio State University)
    • 2024: CITI Good Clinical Practice (The Ohio State University)
    • 2023: Occupational English Test (OET)
    • 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
    • 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
    • 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

    Memberships:

    • American Society of Clinical Oncology (ASCO) - 2022
    • Turkish Society of Medical Oncology - 2020
  • 続きを読む
診察
お問い合わせください
情報

Ercan Ozden

  • 5 優秀 1 レビュー
  • 27年の経験
  • トルコ, イスタンブール, VM Medical Park Pendik Hospital
  • Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.

    Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.

  • 続きを読む
診察
お問い合わせください
情報

Inta Jaunalksne

  • 5 優秀 2 レビュー
  • 49年の経験
  • ラトビア, ユールマラ, Pallas Clinic
  • Dr. Inta Jaunalksne is an experienced immunologist with more than 30 years in the field. She specializes in virotherapy. She graduated from Riga Medical Institute and completed an internship in Internal Medicine. Dr. Jaunalksne is recognized as an expert in immunology.

    She leads the Clinical Immunology Center at Pauls Stradins Clinical University Hospital. Dr. Jaunalksne has played a key role in advancing virotherapy and immunological research. Her work has improved treatment results and introduced new therapies. She is well respected in clinical immunology.

  • 続きを読む
情報

Thomas Mansfeld

  • 4.6 優秀 130 レビュー
  • ドイツ, ハンブルク, Asklepios Hospital Barmbek
  • Senior surgeon of the “Gastrointestinal Medicine: General and Abdominal Surgery – Gastroenterology and Endoscopy” Department

ガンマナイフ
$10,388.16 - $12,696.64
胃癌化学療法
$3,116.45 - $4,039.84
情報

Gul Alco

  • 5 優秀 3 レビュー
  • 31年の経験
  • トルコ, イスタンブール, Medipol Acibadem District Hospital
  • Education

    • 1986-1989, Bursa High School, Bursa, Turkey
    • 1989-1995, Istanbul University, Istanbul School of Medicine, Turkey
    • 1999-2003, (Residency) Kadir Has University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey
    • 2015, (Associate Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
    • 2021, (Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
    • 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

    Experience

    • 1995-1999, Şişli Florence Nightingale Hospital, Istanbul, Cardiology Department
    • 2003, Gayrettepe Florence Nightingale Hospital, Istanbul, Department of Radiation Oncology
    • 2015, (Associate Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
    • 2021, (Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
    • 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey
  • 続きを読む
診察
お問い合わせください
情報

Seyda Gunduz

  • 4.3 良い 18 レビュー
  • 16年の経験
  • トルコ, イスタンブール, Istinye University Liv Hospital Bahcesehir
情報

Muzaffer Al

  • 4.3 良い 4 レビュー
  • 16年の経験
  • トルコ, イスタンブール, Büyük Anadolu Hospitals (BAH International)
  • Education

     

    Ondokuz Mayıs University Faculty of Medicine (1991)

    KTÜ Faculty of Medicine Farabi Hospital (Specialization.1998)

    Istanbul University Çapa Faculty of Medicine (Laparoscopic Surgery Training, 2002)

    Istanbul University Çapa Faculty of Medicine (Laparoscopic Antireflux Surgery Training, 2006)

    Istanbul University Cerrahpaşa Faculty of Medicine (General Surgery Clinic Advance Laparoscopic Surgery, Laparoscopic Bariatric Surgery, Morbid Obesity and Oncological Cancer Surgery Training, 2010i)

     

     

     

     

  • 続きを読む
診察
お問い合わせください
情報

Nail Paksoy

  • 4.5 良い 2 レビュー
  • 15年の経験
  • 認定:
  • トルコ, イスタンブール, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • 続きを読む
胃がんの放射線治療
$4,000 - $6,000
胃切除術
$10,000 - $12,000
腹腔内温熱化学療法
$18,000 - $25,000
情報

Atakan Topcu

  • 5 優秀 3 レビュー
  • 13年の経験
  • トルコ, イスタンブール, Medipol Acibadem District Hospital
  • Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

    He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

    Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

  • 続きを読む
診察
お問い合わせください
情報

Volkan Kinas

  • 4.3 良い 4 レビュー
  • 11年の経験
  • トルコ, イスタンブール, Büyük Anadolu Hospitals (BAH International)
  • Specializations

     

    Cancer Surgery

    Pancreatic Surgery

    Bile Duct Surgery

    Bariatric Metabolic Surgery

    Oncological Surgery

    Breast Surgery

    Gastric cancer

    Colon cancer

    Thyroid Cancer

    Obesity Surgery

    Diabetes Surgeries

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

  • 続きを読む
診察
お問い合わせください
情報

Ezgi Sevic

  • 5 優秀 1 レビュー
  • 7年の経験
  • トルコ, イズミル, Assoc.Prof.Dr.Cemal Kara / Medical Park İzmir Hospital
  • NUTRITION AND DIET SPECIALIST 

    Ezgi Sevic graduated from Hacettepe University, Department of Nutrition and Dietetic as Honor Student. During her education, she conducted studies on “'The Effect of Hedonic Eating Behavior on Obesity', 'Total Parenteral Nutrition in Children' and 'The Relationship Between Insulin Resistance and Obesity'.” During her education, she took part in the field in studies on determining the nutritional status of the society. She worked as intern dietitian in Hospitals of Hacettepe University (Oncology Hospital, Adults Hospital, İhsan Doğramacı Child Hospital), Dışkapı Yıldırım Beyazıt Training and Research Hospital and many Community Health Centres. 
    She worked in Izmir Private Ekol Hospital. She successfully completed the 'Bariatric Nutrition Course' and the 'Innovations in Obesity Course'. She has participated in many training and seminar programs in her field. 

    Interests: Post- Metabolic and Bariatric Surgery Nutrition, the Nutrition in Chronicle Diseases, Nutrition in Individuals with Diabetes, Nutrition in Cancer, Nutrition in Congenital Metabolic Diseases, Food Intolerances, Body Weight Control, Child and Adolescent Nutrition, Nutrition in Old Age, Nutrition in Pregnancy and Lactation.

    Dietit. Ezgi Sevic knows advanced English. 

  • 続きを読む
診察
お問い合わせください
情報

joseba Rebollo Liceaga

  • 4.3 良い 4 レビュー
  • 36年の経験
  • スペイン, アリカンテ, Quironsalud Torrevieja
  • Dr. Joseba Rebollo Liceaga is a seasoned medical oncologist with a comprehensive background in oncology.​

    Education and Training:

    Graduated in Medicine and Surgery from the University of Navarra (1985).​

    Completed residency in Oncology in 1987.​

    Specialist in Medical Oncology at the Clínica Universidad de Navarra (1991).​

    Professional Experience:

    Head of the Oncology Department at Clínica San Miguel de Navarra (1991–2004).​

    Associate Physician at the University Clinic of the Faculty of Medicine, University of Navarra (1995–2002).​

    Adjunct Physician at the Oncology Platform, Hospital Quirónsalud Torrevieja (2004–2014).

    Head of the Oncology Department at Hospital General de Villalba (2014–2019).​

    Currently practices as a Medical Oncology Specialist at Quirónsalud Alicante.​

    Certifications and Training:

    Completed multiple accredited courses in Multidisciplinary Oncology between 2003 and 2006.​

    Research and Publications:

    Authored research on electrochemotherapy and multidisciplinary treatment approaches in oncology.

  • 続きを読む
診察
お問い合わせください
情報

Ayse Irem Yasin

  • 5 優秀 3 レビュー
  • 15年の経験
  • トルコ, イスタンブール, Medipol Acibadem District Hospital
  • Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

    She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

  • 続きを読む
診察
お問い合わせください
情報

Michele Reni

  • 4.6 優秀 66 レビュー
  • 38年の経験
  • イタリア, ミラノ, San Raffaele
  • Professor Michele Reni is an experienced medical oncologist with over 30 years of practice based in Italy. He specializes in pancreatic adenocarcinoma, gastro-esophageal cancers, and central nervous system tumors. He has published over 180 papers on cancer treatment and is the coordinator of Italian Association of Medical Oncology (AIOM) guidelines for treatment and management of pancreatic cancer. He has also chaired numerous clinical trials on treating patients with metastatic pancreatic cancer.

  • 続きを読む
情報

Edoardo Beretta

  • 4.6 優秀 66 レビュー
  • イタリア, ミラノ, San Raffaele
情報